Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 2.5% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) dropped 2.5% during trading on Thursday . The stock traded as low as $22.05 and last traded at $22.32. Approximately 6,067 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 204,738 shares. The stock had previously closed at $22.90.

Analysts Set New Price Targets

DNTH has been the topic of a number of research reports. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Oppenheimer raised their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Stock Down 1.1 %

The company has a 50-day moving average price of $25.23 and a 200-day moving average price of $26.66. The company has a market capitalization of $673.04 million, a price-to-earnings ratio of -9.10 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently bought and sold shares of DNTH. Quest Partners LLC grew its position in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. Fred Alger Management LLC grew its position in Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after buying an additional 3,316 shares in the last quarter. SG Americas Securities LLC increased its stake in Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after acquiring an additional 4,506 shares during the period. MetLife Investment Management LLC raised its holdings in Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after acquiring an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after acquiring an additional 8,473 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.